Veeda Lifesciences Transitions to CRO-CDMO Model with New Brand Identity

• Veeda Group has rebranded as Veeda Lifesciences, marking a shift from generics-focused CRO to a drug development services enterprise.

• The new brand identity reflects the company’s expansion into multiple drug modalities and integrated research services.

Veeda Lifesciences has unveiled a new logo and brand identity, symbolising a significant transformation from its origins as a generics-focused Contract Research Organization (CRO) to a comprehensive drug development services provider. The rebranding reflects the company’s broadened capabilities, offering services across various drug modalities, including generics, novel chemical entities, and biologics. The new identity also aligns with Veeda’s transition to a combined CRO-CDMO model, enhancing its global footprint in the pharmaceutical industry.

Founded in 2004 in India, Veeda Lifesciences now operates in five countries and conducts trials in 26 geographies worldwide. The company’s strategic acquisition of Bioneeds India in 2021 allowed Veeda to expand its service offerings into preclinical testing. As a result, Veeda Lifesciences is now organised into four Strategic Business Units: Clinical Trials, Healthy Volunteer Services, Biopharma Services, and Preclinical & Non-Clinical Testing Services.

Dr. Mahesh Bhalgat, Group CEO and Managing Director of Veeda Lifesciences, commented, “The name – Veeda Lifesciences – and the new logo, designed to be modern and dynamic, symbolize the Group’s forward-thinking approach and dedication to its core values and mission. It adds aspirational value to our growth and vision for the future, striving for innovation, excellence, and client satisfaction.”

Veeda Lifesciences now offers an integrated portfolio of services, ranging from discovery research to late-phase development, supporting global pharma companies with innovative solutions. The new brand identity reinforces the company’s commitment to meeting the growing needs of the life sciences and healthcare industries, marking an exciting new chapter in its evolution.